Obermatt

Yuhan

KSC:000100 · KR7000100008
PharmaceuticalsMedium

360

32
EV / EBIT6
Price / Owner Earnings31
Owner Earnings Yield54
Dividend Yield69
Price/Sales24
EV / Gross Profit34
Price/Book25
Return on Capital33
Cash Return on Capital46
Return on Equity42
EBIT Margin16
Gross Profitability25
Cash Conversion10
Accruals36
Owner Earnings Margin34
Sales growth36
Profit Growth71
Long-Term EPS Growth87
Owner Earnings Growth96
Reinvestment10
Price momentum19
Debt load76
Refinancing32
Debt Payback100
Liquidity64
Analyst ratings44
Opinion Changes80
Price Target Upside86
Market mood98
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Yuhan clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountrySouth Korea
IndustryPharmaceuticals
SizeMedium
TypePublic Company
ExchangeKOSE
Employees236
ISINKR7000100008
Last UpdateApr 2, 2026
Themes
DiabetesCardiovascularInfectious DiseasesCentral Nervous SystemNeurologyBiotechnologyPharmaceutical

Description

Analysis

Weak and unloved

Yuhan Corporation is weak and unloved: below-average business metrics and a price that reflects that disappointment.

The price is expensive. You pay 30.8× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 12% yearly growth; analysts expect 27%. The price, in other words, assumes less than the experts do.

The trajectory is moderate and the balance sheet is adequate. The company scores 10/20 on our value-creation score: creating some value.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
54
2023202420252026

All-time high

59

Mar 2026

All-time low

19

Jan 2024

Average rank

41

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
24
20
34
41
Price/Earnings
6
5
14
18
Price/Book
25
12
27
31
Dividend Yield
69
25
28
25
Value (overall)
25
12
18
23

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Yuhan with its peers
Reyon Pharmaceutical
KSC:102460
16
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Sumitomo Dainippon Pharma
TYO:4506
79
CountryJapan
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Chong Kun Dang
KSC:185750
55
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Handok
KSC:002390
15
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Ono Pharmaceutical
TYO:4528
87
CountryJapan
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Hanall Biopharma
KSC:009420
30
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →